NASDAQ:IDXX

IDEXX Laboratories - IDXX Stock Forecast, Price & News

$348.59

+11.91 (+3.54%)

(As of 10/4/2022 12:00 AM ET)

Add

Compare

Today's Range: $343.10
▼
$352.39
50-Day Range: $325.80
▼
$407.78
52-Week Range: $318.50
▼
$672.93

Volume: 539,058 shs
Average Volume: 553,062 shs
Market Capitalization: $29.02 billion

P/E Ratio: 44.98
Dividend Yield: N/A
Price Target: $483.57

IDEXX Laboratories MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 38.7% Upside
$483.57 Price Target
Short Interest: Healthy
2.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.68
Upright™ Environmental Score
News Sentiment: 1.27
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 21.87%
From $7.91 to $9.64 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.97 out of 5 stars

Medical Sector

22nd out of 1,087 stocks

Diagnostic Substances Industry

1st out of 16 stocks

4.4

Analyst's Opinion

Consensus Rating
IDEXX Laboratories has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $483.57, IDEXX Laboratories has a forecasted upside of 38.7% from its current price of $348.59.
Amount of Analyst Coverage
IDEXX Laboratories has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
2.58% of the float of IDEXX Laboratories has been sold short.
Short Interest Ratio / Days to Cover
IDEXX Laboratories has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in IDEXX Laboratories has recently increased by 10.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
IDEXX Laboratories does not currently pay a dividend.
Dividend Growth
IDEXX Laboratories does not have a long track record of dividend growth.

2.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
IDEXX Laboratories has received a 21.18% net impact score from Upright. Idexx Laboratories seems to create the most significant positive value in categories "Taxes", "Jobs", and "Physical diseases". The positive contribution in the "Physical diseases" impact category is mostly driven by its "Private medical laboratory services", "Veterinary laboratories for pets", and "Veterinary services for livestock" products. See details.
Environmental Sustainability
The Environmental Impact score for IDEXX Laboratories is -1.68.

2.9

News and Social Media Coverage

News Sentiment
IDEXX Laboratories has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for IDEXX Laboratories this week, compared to 4 articles on an average week.
Search Interest
Only 8 people have searched for IDXX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
13 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is an increase of 333% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IDEXX Laboratories insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.06% of the stock of IDEXX Laboratories is held by insiders.
Percentage Held by Institutions
88.45% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for IDEXX Laboratories are expected to grow by 21.87% in the coming year, from $7.91 to $9.64 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IDEXX Laboratories is 44.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 114.97.
Price to Earnings Ratio vs. Sector
The P/E ratio of IDEXX Laboratories is 44.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.72.
Price to Earnings Growth Ratio
IDEXX Laboratories has a PEG Ratio of 4.49. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
IDEXX Laboratories has a P/B Ratio of 42.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IDEXX Laboratories (NASDAQ:IDXX) Stock

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

October 2, 2022 | finance.yahoo.com

IDEXX Laboratories, Inc. (IDXX)

September 23, 2022 | nasdaq.com

RSI Alert: Idexx Laboratories (IDXX) Now Oversold

October 5, 2022 | Investing Trends (Ad)

GRAPHITE: "Essential for America's National Defense"

Did you know each EV battery contains up to 220 pounds of graphite and China controls more than 90% of the world's graphite trade? But now that the U.S. has classified it as "essential for America's National Defense"... one little-known company could become America's ONLY fully integrated graphite provider.

September 8, 2022 | forbes.com

Should You Buy IDEXX Laboratories Stock At Around $350?

September 1, 2022 | finance.yahoo.com

Why Is Idexx (IDXX) Down 14.6% Since Last Earnings Report?

August 30, 2022 | finance.yahoo.com

Baron Funds Believes IDEXX Laboratories (IDXX) has the Strongest Competitive Position Ever

August 22, 2022 | nasdaq.com

First Week of April 2023 Options Trading For Idexx Laboratories

August 19, 2022 | money.usnews.com

Idexx Laboratories, Inc.

October 5, 2022 | Investing Trends (Ad)

GRAPHITE: "Essential for America's National Defense"

August 19, 2022 | nasdaq.com

As IDEXX Laboratories, Inc.'s (NASDAQ:IDXX)) market cap dropped by US$1.8b, insiders who sold US$3.0m worth of stock were able to offset their losses

August 18, 2022 | finance.yahoo.com

OCPNY vs. IDXX: Which Stock Should Value Investors Buy Now?

August 8, 2022 | seekingalpha.com

IDEXX Laboratories Stock Is Very Expensive

August 8, 2022 | americanbankingnews.com

IDEXX Laboratories (NASDAQ:IDXX) Price Target Cut to $420.00

August 2, 2022 | seekingalpha.com

IDEXX Laboratories, Inc. (IDXX) CEO Jay Mazelsky on Q2 2022 Results - Earnings Call Transcript

August 2, 2022 | finance.yahoo.com

IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down

August 2, 2022 | finance.yahoo.com

Idexx Laboratories (IDXX) Q2 2022 Earnings Call Transcript

August 2, 2022 | benzinga.com

IDEXX Laboratories Misses on Q2 Earnings, Issues FY22 Guidance Below Consensus

August 2, 2022 | markets.businessinsider.com

IDEXX Laboratories Slashes FY22 Outlook - Update

August 2, 2022 | nasdaq.com

IDEXX Laboratories Inc Q2 Income Drops, misses estimates

August 1, 2022 | msn.com

$1000 Invested In This Stock 15 Years Ago Would Be Worth $3,700 Today

July 27, 2022 | finance.yahoo.com

OCPNY or IDXX: Which Is the Better Value Stock Right Now?

July 26, 2022 | finance.yahoo.com

IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?

July 26, 2022 | finance.yahoo.com

Idexx Laboratories (IDXX) Expected to Beat Earnings Estimates: Should You Buy?

July 25, 2022 | nasdaq.com

Nasdaq 100 Movers: IDXX, ISRG

July 25, 2022 | seekingalpha.com

IDEXX downgraded at Stifel citing overly bullish Street forecasts

July 21, 2022 | markets.businessinsider.com

Where IDEXX Laboratories Stands With Analysts

July 21, 2022 | seekingalpha.com

IDEXX upgraded, Elanco downgraded as Goldman shakes up animal health coverage

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Company Calendar

Last Earnings: 8/02/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:IDXX
CUSIP: 45168D10
CIK: 874716
Web: www.idexx.com
Phone: (207) 556-0300
Fax: 207-556-4346
Employees: 10,350
Year Founded: 1983

Price Target and Rating

Average Stock Price Forecast: $483.57
High Stock Price Forecast: $582.00
Low Stock Price Forecast: $415.00
Forecasted Upside/Downside: +38.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $7.75
Trailing P/E Ratio: 44.98
Forward P/E Ratio: 44.07
P/E Growth: 4.49
Net Income: $744.84 million
Net Margins: 20.07%
Pretax Margin: 24.89%
Return on Equity: 104.47%
Return on Assets: 26.50%

Debt

Debt-to-Equity Ratio: 1.68
Current Ratio: 0.89
Quick Ratio: 0.61

Sales & Book Value

Annual Sales: $3.22 billion
Price / Sales: 9.03
Cash Flow: $10.37 per share
Price / Cash Flow: 33.61
Book Value: $8.14 per share
Price / Book: 42.82

Miscellaneous

Outstanding Shares: 83,250,000
Free Float: 81,539,000
Market Cap: $29.02 billion
Optionable: Optionable
Beta: 1.14

Social Links

Key Executives

Mr. Jonathan J. Mazelsky (Age 61)
Pres, CEO & Director
Comp: $3.07M

Mr. Brian P. McKeon (Age 60)
CFO, Exec. VP & Treasurer
Comp: $1.43M

Mr. James F. Polewaczyk (Age 58)
Exec. VP & Chief Commercial Officer
Comp: $1.19M

Mr. Michael J. Lane (Age 54)
Exec. VP and GM of Reference Laboratories & Information Technology
Comp: $1.19M

Dr. Nimrata Khatra Hunt P.E. (Age 54)
Ph.D., Exec. VP and GM - Point of Care Diagnostics & Worldwide Operations
Comp: $1.18M

Mr. John Hart
Sr. VP of Worldwide Operations

Mr. Jeffery D. Chadbourne (Age 46)
Sr. Director of Accounting & Financial Reporting

Dr. Martin Smith Ph.D. (Age 54)
Exec. VP & CTO

Mr. Ken Grady
Sr. VP & Chief Information Officer

Ms. Sharon E. Underberg (Age 61)
Exec. VP, Gen. Counsel, & Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IDXX Stock - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDXX shares.
View IDXX analyst ratings or view top-rated stocks.
What is IDEXX Laboratories' stock price forecast for 2022?: 8 Wall Street research analysts have issued twelve-month price objectives for IDEXX Laboratories' shares. Their IDXX share price forecasts range from $415.00 to $582.00. On average, they expect the company's stock price to reach $483.57 in the next year. This suggests a possible upside of 38.7% from the stock's current price.
View analysts price targets for IDXX or view top-rated stocks among Wall Street analysts.
How have IDXX shares performed in 2022?: IDEXX Laboratories' stock was trading at $658.46 at the start of the year. Since then, IDXX stock has decreased by 47.1% and is now trading at $348.59.
View the best growth stocks for 2022 here.
When is IDEXX Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our IDXX earnings forecast.
How were IDEXX Laboratories' earnings last quarter?: IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Tuesday, August, 2nd. The company reported $1.56 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.02. The firm earned $860.55 million during the quarter, compared to the consensus estimate of $864.26 million. IDEXX Laboratories had a trailing twelve-month return on equity of 104.47% and a net margin of 20.07%.
What guidance has IDEXX Laboratories issued on next quarter's earnings?: IDEXX Laboratories issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of $7.77-$8.05 for the period, compared to the consensus EPS estimate of $8.27. The company issued revenue guidance of $3.31 billion-$3.38 billion, compared to the consensus revenue estimate of $3.42 billion.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?: 40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.
What other stocks do shareholders of IDEXX Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).
What is IDEXX Laboratories' stock symbol?: IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."
Who are IDEXX Laboratories' major shareholders?: IDEXX Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Spence Asset Management (0.05%) and Capital Investment Services of America Inc. (0.05%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends.
How do I buy shares of IDEXX Laboratories?: Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is IDEXX Laboratories' stock price today?: One share of IDXX stock can currently be purchased for approximately $348.59.
How much money does IDEXX Laboratories make?: IDEXX Laboratories (NASDAQ:IDXX) has a market capitalization of $29.02 billion and generates $3.22 billion in revenue each year. The company earns $744.84 million in net income (profit) each year or $7.75 on an earnings per share basis.
How many employees does IDEXX Laboratories have?: The company employs 10,350 workers across the globe.
How can I contact IDEXX Laboratories?: IDEXX Laboratories' mailing address is ONE IDEXX DRIVE, WESTBROOK ME, 04092. The official website for the company is www.idexx.com. The company can be reached via phone at (207) 556-0300, via email at investorrelations@idexx.com, or via fax at 207-556-4346.

This page (NASDAQ:IDXX) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IDEXX Laboratories - IDXX Stock Forecast, Price & News

IDEXX Laboratories MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows